Jason Lettmann - Net Worth and Insider Trading
Jason Lettmann Net Worth
The estimated net worth of Jason Lettmann is at least $579 Million dollars as of 2024-11-10. Jason Lettmann is the Director of Ra Pharmaceuticals Inc and owns about 12,053,491 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $578 Million. Jason Lettmann is also the CHIEF EXECUTIVE OFFICER of ALX Oncology Holdings Inc and owns about 171,620 shares of ALX Oncology Holdings Inc (ALXO) stock worth over $248,849. Details can be seen in Jason Lettmann's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Lettmann has not made any transactions after 2024-03-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jason Lettmann
Jason Lettmann Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jason Lettmann owns 2 companies in total, including ALX Oncology Holdings Inc (ALXO) , and Ra Pharmaceuticals Inc (RARX) .
Click here to see the complete history of Jason Lettmann’s form 4 insider trades.
Insider Ownership Summary of Jason Lettmann
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc | 2024-03-14 | director & 10 percent owner |
| RARX | Ra Pharmaceuticals Inc | 2017-06-20 | director & 10 percent owner |
Jason Lettmann Latest Holdings Summary
Jason Lettmann currently owns a total of 2 stocks. Among these stocks, Jason Lettmann owns 12,053,491 shares of Ra Pharmaceuticals Inc (RARX) as of October 31, 2016, with a value of $578 Million and a weighting of 99.96%. Jason Lettmann also owns 171,620 shares of ALX Oncology Holdings Inc (ALXO) as of March 14, 2024, with a value of $248,849 and a weighting of 0.04%.
Latest Holdings of Jason Lettmann
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RARX | Ra Pharmaceuticals Inc | 2016-10-31 | 12,053,491 | 47.99 | 578,447,033 |
| ALXO | ALX Oncology Holdings Inc | 2024-03-14 | 171,620 | 1.45 | 248,849 |
Holding Weightings of Jason Lettmann
Jason Lettmann Form 4 Trading Tracker
According to the SEC Form 4 filings, Jason Lettmann has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 340 shares on October 31, 2016, which brought Jason Lettmann around $4,420.
According to the SEC Form 4 filings, Jason Lettmann has made a total of 4 transactions in ALX Oncology Holdings Inc (ALXO) over the past 5 years, including 2 buys and 2 sells. The most-recent trade in ALX Oncology Holdings Inc is the acquisition of 4,400 shares on March 14, 2024, which cost Jason Lettmann around $49,764.
Insider Trading History of Jason Lettmann
- 1
Jason Lettmann Trading Performance
GuruFocus tracks the stock performance after each of Jason Lettmann's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Lettmann is 11.66%. GuruFocus also compares Jason Lettmann's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Lettmann within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jason Lettmann's insider trading performs compared to the benchmark.
Performance of Jason Lettmann
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 21.29 | | | | | |
| Relative Return to S&P 500(%) | 19.02 | | | | | |
Jason Lettmann Ownership Network
Ownership Network List of Jason Lettmann
Ownership Network Relation of Jason Lettmann
Jason Lettmann Owned Company Details
What does ALX Oncology Holdings Inc do?
Who are the key executives at ALX Oncology Holdings Inc?
Jason Lettmann is the director & 10 percent owner of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include VP & Finance and CAO Shelly Pinto , Chief Medical Officer Sophia Randolph , and director & President and CEO Jaume Pons .
ALX Oncology Holdings Inc (ALXO) Insider Trades Summary
Over the past 18 months, Jason Lettmann made 1 insider transaction in ALX Oncology Holdings Inc (ALXO) with a net purchase of 4,400. Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 145,903 shares made by Jaume Pons , a net sale of 14,288 shares made by Shelly Pinto , and a net sale of 18,243 shares made by Sophia Randolph .
In summary, during the past 3 months, insiders sold 3,866 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 0 shares, with a net sale of 3,866 shares. During the past 18 months, 179,321 shares of ALX Oncology Holdings Inc (ALXO) were sold and 28,400 shares were bought by its insiders, resulting in a net sale of 150,921 shares.
ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.
ALX Oncology Holdings Inc Insider Transactions
Jason Lettmann Mailing Address
Above is the net worth, insider trading, and ownership report for Jason Lettmann. You might contact Jason Lettmann via mailing address: C/o Ra Pharmaceuticals, Inc., 87 Cambridgepark Drive, Cambridge Ma 02140.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
